Special Issue "Antibody Engineering"
A special issue of Antibodies (ISSN 2073-4468).
Deadline for manuscript submissions: closed (20 September 2014)
Dr. Thomas Böldicke
Recombinant Protein Expression/Intrabody Unit, Helmholtz-Centre for Infection Research, Inhoffenstraße 7, D 38124 Braunschweig, Germany
Interests: antibody engineering; selection of human antibodies; cancer therapy; intracellular antibodies
Antibody engineering has revolutionized the current generation of antibodies, which are needed for detection of proteins, analysis and inhibition of protein functions, as well as diagnostic and therapeutic purposes. Human, chimeric and humanized antibodies with high specificity and affinity can now be generated by antibody engineering. Chimeric or humanized variants of mouse antibodies are applied in the clinic. Fusion of antibodies with cytokines, immunotoxins, specific Fc receptors and different signal peptides can be engineered. Phage display of large collections of antibody fragments enables the selection of specific antibodies in vitro. Many human antibodies selected by phage display are being studied and are showing promise in clinical trials.
This Special Issue on antibody engineering will present new technology developments and in vitro and in vivo applications of new engineered antibodies. Researchers will present their latest results and Review articles will cover new developments in the field.
Dr. Thomas Böldicke
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 300 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- human antibody libraries
- cell surface display systems
- ribosomal and mRNA display
- expression and purification of recombinant antibodies
- bispecific antibodies
- intracellular antibodies
- therapeutic antibodies
- in vitro affinity maturation
- improving folding and stability of recombinant antibodies